98%
921
2 minutes
20
The evolving landscape of opioid prescription practices necessitates a comprehensive understanding of emerging patterns, particularly among new opioid users discharged from emergency departments. This study delves into the intricate realm of opioid utilization by elucidating the prevalence of their prescriptions. A retrospective analysis of electronic health records was conducted, including a cohort of 71 patients who received opioid prescriptions upon discharge from emergency departments from 1 January 2022 to 30 June 2022. Demographic characteristics and prescription details were systematically examined. This study illuminates tramadol's prominence, with 84% of prescriptions and a Defined Daily Dose (DDD) morphine equivalent of 60 mg, as the primary choice as a new opioid, a finding that draws attention due to the closely aligned dosages with morphine equivalents. This discovery prompts a critical reassessment of tramadol's therapeutic role, considering its multifaceted nature encompassing serotonergic effects and heightened fall risks. This study advocates for a nuanced and vigilant approach to tramadol prescription, cognizant of its potential risks and therapeutic implications, and highlights the imperative of optimizing data quality and traceability within electronic health records to enhance patient care and facilitate future research endeavors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11171693 | PMC |
http://dx.doi.org/10.3390/healthcare12111138 | DOI Listing |
Drug Saf
September 2025
School of Health Policy and Management, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada.
Introduction: At times it is necessary to withdraw drugs after they have been approved because of lack of effectiveness or safety concerns. Health Canada does not keep a list of withdrawn drugs.
Objective: The aim of this study was to generate a list of all drugs approved since 1990 and subsequently withdrawn from the Canadian market for safety or effectiveness reasons until the end of 2024.
Perm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFArch Psychiatr Nurs
October 2025
University of Pittsburgh School of Nursing, Department of Health and Community Systems, 3500 Victoria St. Pittsburgh, PA 15213, United States of America. Electronic address:
Background: Women veterans are at risk for substance use and substance use disorders, although there remains limited data on substance use in women veterans.
Methods: A secondary analysis of data from the National Survey on Drug Use and Health from 2015 to 2019 and 2021 was conducted to compare women veterans with women non-veterans and men veterans on substance-related outcomes, including lifetime substance use, frequency of past 30-day substance use, and past-year substance use disorders for cannabis, opioids, and stimulants.
Results: From 2015 to 2019, women veterans were about 53 % and 24 % more likely to have used cannabis in their lifetime compared to women non-veterans and men veterans, respectively.
Am J Prev Med
September 2025
Kaiser Permanente Northern California, Division of Research, Center for Addiction and Mental Health Research, Pleasanton, CA, United States.
Introduction: Prescription opioid dose reductions can raise the risk of adverse events for patients on long-term opioid therapy for non-cancer pain. Evidence on whether risks differ by age or sex is needed to support tailored clinical decision-making.
Methods: In 2024, a secondary analysis of an observational cohort study was conducted across 8 U.
Cancer Med
September 2025
Department of Biostatistics & Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas, USA.
Introduction: Chronic pain is a major but modifiable contributor to poor quality of life among long-term cancer survivors. With growing concern over opioid-related risks, gabapentinoids have emerged as a safer alternative, though evidence comparing their effectiveness remains limited.
Methods: We conducted a retrospective cohort study using SEER-MHOS linked data (1998-2021) to examine pain interference and health-related quality of life (HRQoL) among 24,651 cancer survivors.